Home » FDA Clears Trial for ProNAi’s First Drug Candidate
FDA Clears Trial for ProNAi’s First Drug Candidate
ProNAi Therapeutics will begin Phase I trials with its first drug candidate, PNT2258, a potential treatment for several cancer types.
In preclinical research, PNT2258 has shown promising single-agent and combination-therapy efficacy as well as relevant drug-dose response in hematological and solid tumors, ProNAi said.
ProNAi also has partnered with Germany’s Novosom and Austria’s Polymun to develop liposome-based technologies to deliver its DNAi oligonucleotides.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May